The chart below shows how PRPO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PRPO sees a -6.16% change in stock price 10 days leading up to the earnings, and a +5.59% change 10 days following the report. On the earnings day itself, the stock moves by +2.06%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Case Volume Milestone: We recently crossed the 10,000 case mark for the year, compared to close to 8,000 in 2023.
Pathology Revenue Increase: For the second consecutive quarter, our pathology revenues exceeded the division breakeven point and at 4.5 million per quarter represent a robust 18% increase from the previous quarter of Q2.
Quarterly Revenue Increase: Q3 revenues increased by 13% over Q2 reaching $680,000.
Customer Pipeline Development: We are building a robust customer pipeline among which we have three key customers who are in various onboarding stages.
Product Margin Comparison: The margins for our products are significantly higher than those generated by the pathology services division.
Negative
Pathology Revenue Increase: For the second consecutive quarter, our pathology revenues exceeded the division breakeven point and at 4.5 million per quarter represent a robust 18% increase from the previous quarter of Q2.
Quarterly Revenue Increase: Q3 revenues increased by 13% over Q2 reaching $680,000.
Cash Burn Reduction: Our cash balance from the end of Q2 to the end of Q3 was $226,000 in cash burn, compared to approximately $1 million of cash burn during the same period in 2023, a reduction of 75% in our cash burn.
Breakeven Goal Update: We declared our goal of reaching breakeven in 2024, but we have not yet achieved this milestone in the products division, which has not yet hit breakeven.
Sales Team Expansion: Our current sales team of five members enabled us to deliver this revenue, but we may be hiring one more sales person to provide additional revenue stability.
Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript
PRPO.O
-3.85%